Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pmcb IND in June, July 2017? I didn’t think so....lol
Quote:
“Haha....how’s about 3030? I don’t think so....lol”
Forgetting “or it could”? As that is the reason like it or not.
Quote:
It doesn't mean there's any problem with the company or any development.
No it means the end, complete, finished. FAILURE
You have and you are correct. The future isn’t outdated chemo treatment. CAR-T is the promising choice.
Quote:
“This is what I've been saying for the past year--immunotherapy and targeted therapy is the way forward.
They sure did!
Quote:
“TGen receives $2.5 million SU2C grant for new pancreatic cancer clinical trial”
I wonder why Dr. Von Hof didn’t pick ciab. Unlike investors he has no faith I guess.
Dr. Daniel Von Hoff, TGen Distinguished Professor and Physician-In-Chief, will lead a pancreatic cancer clinical trial that will pair an immunotherapy drug called pembrolizumab (trademarked as Keytruda®), with a Vitamin D Receptor (VDR) agonist called paricalcitol (trademarked as Zemplar®).
https://www.eurekalert.org/pub_releases/2017-10/ttgr-tr101217.php
Someone is dumping a lot of shares today. Not good!
Was that the one investors voted over and over again on? Ya that’s legit....
“PMCB won the 2017 Pipelines of Promise award”
And Jansen does? Nope
Like June, July, Aug, Sept, October isn’t happening either. Neither is November or December. It wont be long til KW walks away from pmcb taking millions leaving investors dazed and confused.
Misery loves company?
Pmcb has caused a lot of misery to many investors. Buyer Beware if this share selling SCAM.
QUOTE:
“Why I'm long PMCB and you should be”
PMCB. FDA WARNS OF Thwarting a Stem Cell Scheme
In December 2011, three men were arrested in the United States and charged with 15 counts of criminal activity related to manufacturing, selling and using stem cells without FDA sanction or approval.
According to the criminal indictment, one of the accused, a licensed midwife who operated a maternity care clinic in Texas, obtained umbilical cord blood from birth mothers, telling them it was for “research” purposes. Instead, the midwife sold the cord blood to a laboratory in Arizona which, in turn, sent the blood to a paid consultant at a university in South Carolina. The owner of the laboratory in Arizona was convicted in August 2011 of unlawfully introducing stem cells into interstate commerce. She faces up to 3 years in prison and a fine of up to $10,000.
The consultant, an assistant professor, used university facilities to manufacture stem cell products. He then sent the products back to the lab, which sold them to a man representing himself as a physician licensed in the U.S. The man then traveled to Mexico to perform unapproved stem cell procedures on people suffering from cancer, multiple sclerosis and other autoimmune diseases.
The three defendants allegedly received more than $1.5 million from patients seeking treatment for incurable diseases.
“Scammers like these offer false hope to people with incurable diseases in order to line their own pockets with money,” says Special Agent in Charge Patrick J. Holland of FDA’s Office of Criminal Investigations (OCI), Kansas City Field Office. “FDA will continue to aggressively pursue perpetrators who expose the American public to the dangers of unapproved stem cells and ensure that they are punished to the full extent of the law.”
FDA’s OCI worked the case with the Federal Bureau of Investigations and the Internal Revenue Service’s Criminal Investigations Division.
http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm286155.htm
PMCB next?
PMCB EPIC FAILS OF BULLSHIT PROMISES (part 2)
ENJOY!!
Kenner Waggoner quotes:
Initiation of the Phase 2b clinical trial in Australia in patients with advanced pancreatic cancer. This is expected to begin in late 3Q2015.
Initiation of the Phase 1/2 clinical trial on the effectiveness of PharmaCyte’s pancreatic cancer treatment dealing with pain associated with advanced pancreatic cancer. This trial, to be conducted in the U.S., is expected to begin in late 3Q2015.
Initiation of the Phase 1/2 clinical trial on the effectiveness of PharmaCyte’s pancreatic cancer treatment in slowing the accumulation of malignant ascites fluid. This trial, to also be conducted in the U.S., is expected to occur in late 3Q2015 or early 4Q2015.
The initiation of these three clinical trials is dependent on the approval for use of the Cell-in-a-Box® live cell encapsulation facility that has been constructed in Bangkok, Thailand, by our partner, Austrianova. This facility must be approved as being compliant with current Good Manufacturing Practices (cGMP) standards by Thailand’s and Australia’s drug regulatory authorities as well as by the U.S. FDA.
Completion of our laboratory and small animal studies with the Melligen cells that are necessary to develop our treatment for insulin-dependent diabetes. These studies are designed to obtain data that will be required by regulatory authorities before any human clinical trials can occur.
ALL BULLSHIT!!!!
PMCB EPIC FAILS OF BULLSHIT PROMISES (part 1)
ENJOY!!
Q/A with pmcb's Kenneth Waggoner
Q: Can you describe some of the major milestones you’ve been able to accomplish since coming on board?
KENNETH: First and foremost, PharmaCyte Biotech has been completely transformed from a nutraceutical company into a pure biotechnology company. We are no longer in the nutraceutical business. Some of the other major milestones include the following:
The financial position of PharmaCyte Biotech has become the strongest in the Company’s history. We are virtually debt-free and have access to all of the necessary capital required to meet both our short-term and long-term financial commitments.
We are well underway in completing the necessary steps to commence three clinical trials using our Cell-in-a-Box® technology. The first will be a Phase 2b clinical trial of our pancreatic cancer treatment. Our pancreatic cancer treatment will be compared “head-to-head” with the current best available treatment for the disease. This treatment is the combination of gemcitabine with Celgene’s drug Abraxane®. We expect to begin this clinical trial in the third quarter of 2015.
We are also underway in completing preparations for two other clinical trials related to the “quality of life” of patients with advanced pancreatic cancer and other abdominal tumors.
We expect to start both clinical trials late in the third quarter of 2015.
ALL BULLSHIT!!!!
PMCB EPIC FAILS OF BULLSHIT PROMISES (part 3)
Blast from the past >July 2014<
Notice how the dates, design, CRO, locations all have been changed time and time again?? The BULLSHIT continues.
ENJOY!!
Kenneth Waggoner quotes:
Nuvilex has completed the necessary preliminary steps to commence a Phase 2b clinical trial of its pancreatic cancer treatment that it expects to begin in Q1 2015. Nuvilex's treatment (Cell-in-a-Box® plus ifosfamide) will be compared "head-to-head" with the best available therapy (currently Abraxane® plus gemcitabine) for advanced, inoperable pancreatic cancer. The trial will be conducted in Australia where one of that country's leading clinical research organizations (CRO), Clinical Network Services, has been contracted by Nuvilex to conduct all aspects of the trial. Dr. Matthias Löhr, one of Europe's leading oncologists/gastroenterologists with extensive experience in treating pancreatic cancer and the principal investigator for the previous successful Phase 1/2 trials using the Cell-in-a-Box®/ifosfamide combination in pancreatic cancer, has agreed to oversee the Phase 2b trial in Australia.
Nuvilex has also made significant developments towards conducting preclinical and clinical studies related to the "quality of life" of patients with advanced, inoperable pancreatic cancer. Nuvilex expects one of the preclinical studies to begin in early August, 2014, as recently announced. In particular, these studies will help determine if Nuvilex's pancreatic cancer treatment can have beneficial effects on two major symptoms that accompany advanced pancreatic cancer, namely the unbearable and often untreatable pain and the accumulation of malignant ascites fluid in the abdomen. Nuvilex and TD2, America's "Premier Oncology CRO," are expecting the arrival of encapsulated live cells capable of converting the ifosfamide into its cancer-killing form at the TD2 facilities in Scottsdale, Arizona, the first week of August. TD2 is scheduled to begin these studies shortly after the arrival of the encapsulated cells. The initial preclinical studies will concern the accumulation of ascites fluid and, if successful, will lead to clinical trials.
ALL BULLSHIT!!!!
debenture paid via stock
http://www.rug.nl/research/pathology/medbiol/pdf/trendsbiotechnology2004orive.pdf
https://www.researchgate.net/profile/Brian_Salmons/publication/236165642_GMP_Production_of_an_Encapsulated_Cell_Therapy_Product_Issues_and_Considerations/links/02e7e516bda4925bf0000000/GMP-Production-of-an-Encapsulated-Cell-Therapy-Product-Issues-and-Considerations.pdf
I’m always right when it comes to these scams. Tried to warn but the dreams of becoming rich overnight overtook common sense. Scammers prey on that human instinct. Hopefully nobody lost too much.
Quote:
“What about the IND? Or the ne sayers are right,we just stringing along?”
Oh it’s next year now. I see, wow how time flies and pmcb hasn’t done jack shit with ciab since they acquired the license 4-5 years ago. Funny isn’t it?
Takes money to make money.
Kw spends 50k then unloads millions of dollars worth of shares onto suckers buying into his scam. Pretty good trade off.
He’s not dumb, many successful scammers aren’t.
US FDA rejects pmcb it’s lost cause. China isn’t even second best. Like the old saying “can’t polish a turd”
Kw spends 50k for a new rumor giving him more time to make millions selling shares to the new round of hopefuls.
Good post worth reposting.
“Some facts about where this company was when shady Kenny took over PMCB. There were 602,958,014 shares outstanding and they had an Accumulated deficit of $52,229,316. Now there is 973,167,811 shares outstanding and an Accumulated deficit of $90,823,717. So shady Kenny has issued 370,209,797 shares and spent $38,594,401. Beside the $4 million or so given yo Austrianova for rights to CIAB where did all this money go? Pmcb has no buildings or labs. They have not invented anything new that cost $Millions. I bet you all really know where all this money went and continues to go and i bet you really know that no credible company would ever invest in a company whose primary goal is obviously NOT to help people with cancer or any other medical condition.”
FDA rejected CIAB China won’t touch it.
No buyout no IND no FDA blessings for pmcb. Nobody that matters has faith in 20 year old CIAB.
FDA Rejects Pharmacyte past phase 1/2. No IND for pmcb so China is the new bullshit rumor being ran now.
Buyer Beware if this SCAM!
Lmao! Pmcb failed the US FDA so now they’re going to tell investors they’re going to go to China to sell CIAB.
What a joke.
Are there seriously any investors who are going to put up with KW house of lies?
Can’t argue with facts. Numbers don’t lie. Pmcb on the other hand.....
GMP Production of an Encapsulated Cell Therapy Product: Issues and Considerations.
Explanations of why pmcb FAILED by BRIAN SALMONS*, OLIVER HAUSER, WALTER H. GU¨NZBURG and WALTER TABOTTA
One of the major concerns facing relatively young biotechnology compa- nies once a lead prod- uct has been identified is the issue of manufacturing. Usually this involves the upscaling of a lab-scale pro- cess while at the same time, complying with good manufacturing practice (GMP) to ensure a reproducibly- produced and consistent product. It also involves the establishment of specific and robust assays in process controls and release criteria.
https://www.researchgate.net/profile/Brian_Salmons/publication/236165642_GMP_Production_of_an_Encapsulated_Cell_Therapy_Product_Issues_and_Considerations/links/02e7e516bda4925bf0000000/GMP-Production-of-an-Encapsulated-Cell-Therapy-Product-Issues-and-Considerations.pdf
History, challenges and perspectives of cell microencapsulation
Explains pmcb’s failure.
Another challenge is the scaling-up of the manufactur- ing process while maintaining a controlled environment, operational discipline and rigorous quality controls. This step will be essential for allowing cell microencapsulation technology to enter human clinical trials and thereby become a real clinical therapeutic strategy. Another major area of study is the retrievability associated with the microcapsules and the banking and culture of suitable cell
sources. The importance of protocol design in yielding donor cells of adequate quantity and quality is paramount for the success of this technology.
The next step will be likely to involve the development of ‘super-specialized’ microcapsules that embody multiple micro-compartments, each one dynamically interacting with the other, containing cells or pharmacological agents that interact favorably with the ‘primary’ cellular product. Such capsules will not be more complex, chemi- cally or biologically, but will be based on simple engineered materials, assembled in the correct manner. The final aim is to continuously improve cell life expectancy and func- tional performance, and eventually to establish a self- perpetuating cell regeneration pattern, to address the treatment of high social impact diseases, such as diabetes, Parkinson’s disease or Alzheimer ’s disease.
http://www.rug.nl/research/pathology/medbiol/pdf/trendsbiotechnology2004orive.pdf
How many red flags does someone need to realize pmcb is a scam, a Biotech “Zombie Stock”?? The jig is up for pmcb. Buyer Beware
Quote:
“We know austrianova was paid 640,000usd to manufacture our trial materials
Why isn’t that being refunded now they’re not doing it?
And why is it costing 300,000 from Eurofins? Half price for more materials? We know this.
We know austrianova are being paid 900,000usd in a renegotiated deal but we already paid them millions to get our licenses. How come those deals don’t stand? Why did we pay them millions if they aren’t valid?
If you want to deal with what we know you can deal with this.
If we follow the money does it looks like kw is working for austrianova and not us. But we pay his salary right? We know that too. A salary he recently doubled.
I see a lot of money being paid out of the company by kw and no real value to shareholders.
These are things we actually know.
Would you like to deal with them?
And no emails to answer this.
And no returned phone call.
Do you think the kw game might be up and he’s playing for time?
Why can’t we know the answers to these things now?
These are very serious matters involving several million usd.
Why do we have to wait for a ‘planned’ update to know why millions of our money was used this way?”
Because pmcb is a SCAM. Finally seeing the light ya better than never seeing it.
quote:
“Why isn’t our well paid ceo answering investor relations emails?
Why isn’t he returning phone calls? “
For those who think pmcb couldn’t be a scam read up on Theranos. Majority of their BOD and employees didn’t even know.
https://www.google.com/amp/s/www.forbes.com/sites/roomykhan/2017/02/17/theranos-9-billion-evaporatedstanford-expert-whose-questions-ignited-the-unicorn-trouble/amp/
Safe Harbor aka scammer protection
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.
Pmcb = DEAD MONEY!
Markets making all time highs and PMCB continues to fall.
Buyer Beware
Did you know pmcb went to nearly all the same places and did the same things in 2015 and 2016 too? Nothing ever came of of those either.
I don’t know ask Equifax.
I mean what CEO would not want to keep shareholders informed....or semi informed?
Yet none are buying shares.
Quote:
“You don't have to believe it, what about all the doctors (best in cancer field) that join the company.”
Good job general!
“Edit: Note that Kenn Kerr has been removed from the PharmCyte Facebook page today. Any questions deleted were deleted by him without direction or approval by PharmaCyte.”
The truth cannot be hidden. Deleting ppl who voice a concern should be met with open ears not banished. Only the fearful hide the truth.